Preclinical study demonstrates mobile focused ultrasound suppresses tumor growth and enhances immune cell infiltration in pancreatic cancer models, highlighting noninvasive ablation potential.
PURPOSE: High-intensity focused ultrasound (HIFU) is a noninvasive ablation technology with increasing relevance for preclinical research and clinical translation. Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with limited therapeutic options and poor response to current treatments, underscoring the urgent need for alternative strategies. To address this, we developed a mobile HIFU platform optimized for small-animal studies with an immersion-free design that improves usability while maintaining reproducible thermal ablation. MATERIALS AND METHODS: , we further established a co-culture system of tumor organoids and CD8+ T cells. RESULTS: HIFU treatment induced tumor necrosis and significantly suppressed tumor growth. Histological and flow cytometric analyses revealed treatment-associated immune modulation, including increased proportions of activated CD8+ T cells, APC-like cells, and macrophage populations. In the organoid coculture model, activated CD8+ T cells accumulated around tumor organoids and were associated with increased tumor organoid death. CONCLUSIONS: The proposed mobile HIFU system demonstrated reliable technical performance and biological efficacy in a preclinical PDAC model. This platform offers a practical tool for reproducible small-animal HIFU studies and highlights the potential of ultrasound-based tumor ablation as a strategy to address unmet therapeutic needs in pancreatic cancer.
No takes yet. Share an insight, caveat, or question.
Shon et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: